Physician profile
Jon L Freels
NPI 1336200385
$34,970.86
in general payments reported to CMS, 2019-2025
23 companies · $6,457 in 2025
The $6,457 reported for 2025 was more than what 90% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $137 · 2021: $80.59 · 2022: $859 · 2023: $13K · 2024: $14K · 2025: $6,457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Travel and Lodging: $2,911 · Food and Beverage: $2,381 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,145.00 |
| Travel and Lodging | $2,911.02 |
| Food and Beverage | $2,381.13 |
| Education | $148.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $32,365.49 | 2021-2025 | Illumisite, Arcpoint |
| Noah Medical Corporation | $914.91 | 2023 | |
| Pulmonx Corporation | $420.39 | 2022-2024 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Covidien LP | $272.74 | 2019-2020 | |
| Genzyme Corporation | $153.17 | 2022-2025 | |
| Davol INC. | $149.41 | 2025 | Progel Applicator Spray Tips |
| Insmed, INC. | $118.44 | 2019-2024 | Arikayce |
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $73.82 | 2022-2024 | Dupixent |
| Intuitive Surgical, INC. | $63.96 | 2025 | |
| Erbe USA INC | $50.00 | 2025 | Cryo2 |
| Astrazeneca Pharmaceuticals LP | $45.55 | 2024-2025 | Tezspire |
| Philips North America LLC | $45.37 | 2019 | |
| Glaxosmithkline, LLC. | $35.17 | 2020-2025 | Nucala |
| Mallinckrodt Hospital Products INC. | $26.05 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.22 | 2025 | Jascayd |
| Baxter Healthcare | $20.08 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.40 | 2019 | |
| Mylan Specialty L.P. | $16.90 | 2019 | |
| Abbvie INC. | $16.16 | 2025 | |
| Boston Scientific Corporation | $15.56 | 2024 | Exalt Model D |
| Advanced Respiratory, INC | $13.45 | 2021 | |
| Veran Medical Technologies, INC. | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Freels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.